This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Amgen Fremont Inc., Amgen Inc., Medimmune Limited. Active years: 2007-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Pleasanton, CA (US) (2007 - 2012)
- Gaithersburg, MD (US) (2021 - 2022)
Company Filing History:
4 out of 78 
4 out of 2,072 
2 out of 548 
Years Active: 2007-2022
Title: Innovator Spotlight: Raffaella Faggioni
Introduction
Raffaella Faggioni is a prominent inventor based in Pleasanton, California, recognized for her significant contributions to the field of biomedical research. With a remarkable portfolio of 8 patents, she focuses on advancing therapeutic strategies for patients suffering from interleukin-23 (IL23)-mediated diseases, including Crohn's disease. Her innovative work highlights the intersection of molecular biology and clinical application.
Latest Patents
Among Raffaella's latest patents is a groundbreaking invention titled "CCL20 as a predictor of clinical response to IL23-antagonists." This invention employs the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to stratify patient populations suffering from IL23-mediated diseases. The use of CCL20 allows for the assessment of patient eligibility for treatment with anti-IL23 antagonists, guiding clinical decision-making on whether to commence, suspend, or modify therapeutic interventions. Additionally, her other recent patent, "Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers," describes utilizing components of the IL23 pathway—such as IL22 and lipocalin-2 (LCN2)—to effectively identify patients responsive to anti-IL23 therapies.
Career Highlights
Raffaella has built a distinguished career, including her tenure at reputable companies such as Amgen Fremont Inc. and Amgen Inc. Her expertise in developing biomarkers and therapeutic approaches has greatly impacted the way IL23-mediated diseases are treated in clinical settings. Her contributions are pivotal in enhancing patient care through tailored treatments based on biomarker assessments.
Collaborations
Throughout her career, Raffaella has collaborated with several notable individuals, including her coworkers Orit Foord and Scott L Klakamp. These partnerships have fostered an environment of innovation, enabling the successful development and patenting of new medical technologies.
Conclusion
Raffaella Faggioni is a trailblazer in the realm of biomedical innovation. With an impressive array of patents and a commitment to enhancing patient outcomes, she exemplifies the impact of dedicated inventors in the life sciences. As research continues to evolve, Raffaella’s work will undoubtedly contribute to significant advancements in therapeutic strategies for managing chronic diseases like Crohn's disease.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile